KALA BIO, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by KALA BIO, Inc. on July 22, 2026. The report addresses a specific corporate event related to a securities offering rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a legal disclosure regarding a securities offering and does not contain financial performance data.
Material Changes
On July 22, 2026, the Company filed a prospectus supplement pursuant to Rule 424(b) under the Securities Act of 1933. This supplement relates to an offering of securities under the Company's effective Registration Statement on Form S-3 (File No. 333-295667). The primary purpose of this 8-K filing is to provide the legal opinion regarding the validity of the securities being offered.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks beyond the standard legal context of the securities offering. The document includes an attached legal opinion from Haynes and Boone, LLP (Exhibit 5.1) and their consent (Exhibit 23.1).
Investor Verification Checklist
- Verify the details of the securities offering in the referenced prospectus supplement filed under Rule 424(b).
- Review the effective Registration Statement on Form S-3 (File No. 333-295667) for the full scope of the offering.
- Examine Exhibit 5.1 for the specific legal opinion from Haynes and Boone, LLP regarding the validity of the securities.
- Confirm the trading status of Common Stock (Symbol: KALA) on The Nasdaq Capital Market.